| Company Name: |
Jinan Good Medical &Technology Ltd Co., Gold
|
| Tel: |
+86-0086-531-55562571，18953105926 +86-13553167512 |
| Email: |
935170726@qq.com |
| Products Intro: |
Product Name:T9175;A51
CAS:2079068-74-7
Purity:99 Package:100g
|
|
| | Casein Kinase inhibitor A51 Basic information |
| Product Name: | Casein Kinase inhibitor A51 | | Synonyms: | Casein Kinase inhibitor A51;CKIα inhibitor A51;BTX-A51;1,4-Cyclohexanediamine, N1-[5-chloro-4-[5-(cyclopropylmethyl)-1-methyl-1H-pyrazol-4-yl]-2-pyrimidinyl]-, trans-;T9175;BTX-A51 (Casein Kinase inhibitor A51) | | CAS: | 2079068-74-7 | | MF: | C18H25ClN6 | | MW: | 360.88 | | EINECS: | | | Product Categories: | | | Mol File: | 2079068-74-7.mol |  |
| | Casein Kinase inhibitor A51 Chemical Properties |
| Boiling point | 570.0±60.0 °C(Predicted) | | density | 1.48±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | pka | 10.41±0.70(Predicted) | | form | Solid | | color | Off-white to brown |
| | Casein Kinase inhibitor A51 Usage And Synthesis |
| Biological Activity | Casein Kinase inhibitor A51 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A51 induces leukemia cell apoptosis, and has potent anti-leukemic activities[1].
Similar to CKIα depletion, Casein Kinase inhibitor A51 (0.05-3.2 μM; 18 hours) treatment of RKO cells abolished most of the Ser45 phosphorylation signal and the consecutive GSK3 phosphorylation cascade resulting in stabilization of β-catenin[1]. Casein Kinase inhibitor A51 is highly effective in inducing leukemia cell apoptosis at 160 nM or lower, mostly in correlation to their capacity to stabilize p53[1].Casein Kinase inhibitor A51 (0.08-2 μM; 6.5 hours) abolishes the expression of MYC, MDM2, and the anti-apoptotic oncogene MCL1. Casein Kinase inhibitor A51 induces a marked reduction in mRNA expression of MYC and MDM2, yet upregulates the expression of the Wnt targets AXIN2 and CCND1 (Cyclin D1)[1].
Oral treatment is initiated at 8 days (Casein Kinase inhibitor A51; 5 mg/kg/day) after leukemia cell inoculation, at which the percentage of leukemia cells in the BM is more than 1.5% of all cells. all A51-treated mice have normal organ morphology and histology and normal blood counts[1].Pharmacokinetic studies of the inhibitor Casein Kinase inhibitor A51 at 20 mg/kg reveal rapid oral absorption with a Tmax of 0.5-2 hr, Cmax of 1060 ng/mL, T1/2 of 2.5 hr, and area under the curve (AUC) values of 3680 (ng*hr/mL)[1]. | | References | [1]. Waleed Minzel, et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018 Sep 20;175(1):171-185.e25. |
| | Casein Kinase inhibitor A51 Preparation Products And Raw materials |
|